Equities

Cytophage Technologies Ltd

Cytophage Technologies Ltd

Actions
  • Price (CAD)0.32
  • Today's Change-0.005 / -1.54%
  • Shares traded1.50k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 14:53 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cytophage Technologies Ltd. is a Canadian biotechnology company. The Company uses advanced molecular genetic techniques and synthetic biology to create bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria, the Company generates customized phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a phage-display methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health. Its products include FarmPhage, AviPhage, PhageFend, and BoviPhage. FarmPhage is a water-soluble phage solution for livestock. AviPhage is poultry health products offered by the Company.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-7.80m
  • Incorporated2019
  • Employees--
  • Location
    Cytophage Technologies Ltd26 Henlow BayWINNIPEG R3Y 1G4CanadaCAN
  • Phone+1 (416) 214-4810
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Voyageur Pharmaceuticals Ltd0.00-1.53m9.07m----9.60-----0.0112-0.01120.000.00680.00-------67.92-74.47-111.56-120.92--------0.0896-329.900.0406------20.21---11.81--
Khiron Life Sciences Corp16.14m-30.66m9.56m310.00------0.5924-0.1674-0.16740.0850.12480.30781.333.9052,055.68-58.47---69.10--19.51---190.00--0.9133--0.0864--59.60---37.81------
Willow Biosciences Inc2.87m-7.72m11.54m19.00--59.16--4.02-0.0604-0.06040.02220.00140.4901--6.33151,000.00-131.79---193.14-------268.91--0.756--0.9002--42.75--12.05------
Crescita Therapeutics Inc17.40m-2.74m11.89m80.00--0.7406--0.6833-0.1409-0.14090.88910.83710.72431.299.27217,537.50-11.40-0.2457-14.88-0.305955.5863.41-15.73-0.35181.68--0.0545---25.521.05-330.39---1.58--
Kane Biotech Inc757.12k-5.48m14.50m--------19.16-0.0420.03740.0059-0.00550.15680.37513.23---113.43-77.89----60.5443.27-723.31-241.850.5679-4.731.43---94.42-20.26-17.29---19.41--
Pharmacielo Ltd1.62m-14.15m15.82m268.00------9.76-0.0849-0.08490.0097-0.0320.06991.3824.15---61.03---165.82---86.39---873.57--0.039-2.481.37---70.96---12.27------
Cytophage Technologies Ltd0.00-7.80m17.53m----3.32-----0.3779-0.37790.000.0978----------------------------0.2374-------25.88------
Devonian Health Group Inc9.75m-3.17m18.53m6.00--1.39--1.90-0.0216-0.02160.06650.090.442333.072.321,625,238.00-14.37-21.02-23.15-23.9630.9529.96-32.50-131.971.06-9.410.1406--1.74-5.83-33.39------
Data as of Nov 22 2024. Currency figures normalised to Cytophage Technologies Ltd's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.